Physiologically, GLP-1 is known to control body weight gain inhibiting appetite and delaying gastric emptying, and GLP-1 synthetic orally-active receptor agonist semaglutide has now been used to control type-2 diabetes and obesity [111,112,113,114]. This evidence concerns the gene GCG and type 2 diabetes mellitus.